Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy

被引:8
|
作者
Nakajima, Yuki [1 ]
Tomita, Naoto [1 ]
Itabashi, Megumi [2 ]
Miyashita, Kazuho [3 ]
Watanabe, Reina [4 ]
Miyazaki, Takuya [1 ]
Tachibana, Takayoshi [1 ]
Takasaki, Hirotaka [4 ]
Kawasaki, Rika [3 ]
Tanaka, Masatsugu [2 ]
Hashimoto, Chizuko [5 ]
Yamazaki, Etsuko [1 ]
Taguchi, Jun [6 ]
Fujimaki, Katsumichi [3 ]
Sakai, Rika [4 ]
Fujita, Hiroyuki [6 ]
Fujisawa, Shin [2 ]
Harano, Hiroshi [7 ]
Motomura, Shigeki [4 ]
Ishigatsubo, Yoshiaki [1 ]
机构
[1] Yokohama City Univ, Grad Sch Med, Dept Internal Med & Clin Immunol, Yokohama, Kanagawa 2360004, Japan
[2] Yokohama City Univ, Med Ctr, Dept Hematol, Yokohama, Kanagawa 2360004, Japan
[3] Fujisawa City Hosp, Dept Hematol Immunol, Fujisawa, Kanagawa, Japan
[4] Kanagawa Canc Ctr, Dept Med Oncol, Yokohama, Kanagawa 2410815, Japan
[5] Yamato Municipal Hosp, Dept Hematol Oncol, Yamato, Japan
[6] Shizuoka Red Cross Hosp, Dept Hematol, Shizuoka, Japan
[7] Yokosuka City Hosp, Dept Hematol, Yokosuka, Kanagawa, Japan
关键词
Diffuse large B-cell lymphoma; Infra-diaphragmatic; Supra-diaphragmatic; Prognostic factor; Gastrointestinal involvement; EXTRANODAL INVOLVEMENT;
D O I
10.1016/j.leukres.2014.11.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The prognostic implications of infra-diaphragmatic (InD) versus supra-diaphragmatic (SpD) primary lesions in limited-stage diffuse large B-cell lymphoma (DLBCL) remains unknown. This retrospective study aimed to assess the prognostic impact of spD and InD lesions as well as presence of gastrointestinal (GI) involvements in adults with limited-stage DLBCL. We analyzed data from 178 patients with limited-stage DLBCL who were treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy at 7 institutions of the Yokohama City University Hematology Group between 2003 and 2009. The median age was 63 years (range, 18-80 years). The primary sites were SpD in 109 patients, and InD in 69. No statistical differences in progression-free survival (PFS) or overall survival (OS) were observed between patients with SpD lesions and those with InD lesions. However, when patients with SpD lesions, InD lesions with (n = 35), and without (n = 34) GI involvement were compared, the presence of GI lesions was associated with favorable PFS. The multivariate analysis revealed that SpD or InD localization had no independent effect on PFS or OS, whereas the presence of GI lesions was correlated with favorable PFS (P = 0.024, HR 0.09). (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:198 / 203
页数:6
相关论文
共 50 条
  • [41] The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma
    Byeong Seok Sohn
    Sun-Mok Kim
    Dok Hyun Yoon
    Shin Kim
    Dae Ho Lee
    Jin-Ho Kim
    Sang-Wook Lee
    Jooryung Huh
    Cheolwon Suh
    Annals of Hematology, 2012, 91 : 1731 - 1739
  • [42] Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
    Choi, Soyeon
    Lee, Yoo Jin
    Choi, Yunsuk
    Kim, Misung
    Kim, Hyun-Jung
    Kim, Ji Eun
    Oh, Sukjoong
    Chae, Seoung Wan
    Cha, Hee Jeong
    Jo, Jae-Cheol
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2022, 56 (05) : 281 - 288
  • [43] Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge
    Lavacchi, Daniele
    Landini, Ida
    Perrone, Gabriele
    Roviello, Giandomenico
    Mini, Enrico
    Nobili, Stefania
    PHARMACOLOGY & THERAPEUTICS, 2022, 229
  • [44] DOSE ATTENUATION OF R-CHOP FOR THE TREATMENT OF ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
    Choi, Y. J.
    Chung, J. S.
    Lee, K. W.
    Shin, H. J.
    Cho, G. J.
    Song, M. K.
    Seol, Y. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 502 - 502
  • [45] Dose attenuation of R-CHOP for the treatment of elderly patients with diffuse large B cell lymphoma
    Choi, Young Jin
    Lee, Kyung Woo
    Shin, Ho-Jin
    Chung, Jooseop
    Cho, Goon-Jae
    BLOOD, 2007, 110 (11) : 184B - 184B
  • [46] Prognostic Impact of Tumor Microenvironment on Diffuse Large B-Cell Lymphoma Treated with R-CHOP
    Gomez-Gelvez, J. C.
    Salama, M.
    Cogan, C.
    Leavitt, M.
    Inamdar, K.
    LABORATORY INVESTIGATION, 2013, 93 : 329A - 329A
  • [47] Impact of primary prophylaxis by pegfilgrastim in diffuse large B-cell lymphoma treated with R-CHOP
    Kim, Moonho
    Ahn, Yongchel
    Ahn, Heui-June
    Ha, Suk-Hun
    Oh, Ho-Suk
    Song, Jae-Seok
    Park, Woong-Sub
    Yi, Sang-Wook
    ANNALS OF HEMATOLOGY, 2023, 102 (11) : 3167 - 3175
  • [48] Fixed dose rituximab for diffuse large B cell lymphoma treated with R-CHOP - a retrospective audit
    Furtado, M. V.
    Shah, N. K.
    Rule, S. A. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 56 - 56
  • [49] Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma
    Camus, Vincent
    Tilly, Herve
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1047 - 1055
  • [50] Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial
    Kuhnl, Andrea
    Shaikh, Ridwan
    Cunningham, David
    Barrans, Sharon L.
    Burton, Cathy H.
    Jack, Andrew
    Gleeson, Mary
    Counsell, Nicholas
    Smith, Paul
    Schofield, Oliver
    Linch, David C.
    Hubank, Michael
    BLOOD, 2016, 128 (22)